Patents Examined by Changhwa J. Cheu
  • Patent number: 10488308
    Abstract: The present invention is in the field of in vitro diagnostics and relates to a method for preparing lipemic plasma or serum samples and the use thereof for establishing a lipid interference in the quantitative determination of the amount or the activity of an analyte in a plasma or serum sample.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: November 26, 2019
    Inventor: Juergen Patzke
  • Patent number: 10480034
    Abstract: The application discloses new biomarkers and methods useful in the diagnosis, prognosis and/or monitoring of, or as a therapeutic or research target for, solid tumour cancers, such as colorectal cancer, based on measuring the biomarkers; and related kits and devices.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: November 19, 2019
    Inventor: Jeffrey Lordan
  • Patent number: 10473654
    Abstract: Methods and systems for identifying a protein within a sample are provided herein. A panel of antibodies are acquired, none of which are specific for a single protein or family of proteins. Additionally, the binding properties of the antibodies in the panel are determined. Further, the protein is iteratively exposed to a panel of antibodies. Additionally, a set of antibodies which bind the protein are determined. The identity of the protein is determined using one or more deconvolution methods based on the known binding properties of the antibodies to match the set of antibodies to a sequence of a protein.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: November 12, 2019
    Assignee: NAUTILUS BIOTECHNOLOGY, INC.
    Inventor: Parag Mallick
  • Patent number: 10457744
    Abstract: The invention provides TIMP2 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: October 29, 2019
    Assignee: Astute Medical, Inc.
    Inventors: Ravi A. Vijayendran, Srivatsa Venkatasubbarao
  • Patent number: 10451611
    Abstract: The present invention provides compositions exhibiting in vivo activity of fibrin in an in vitro setting, in vitro assays comprising such compositions, methods of producing such compositions, and methods of using such compositions and assays. The compositions of the invention include molecules with the biochemical properties of 1) high affinity binding to fibrin receptors and 2) activation of cell-signaling systems comparable to that observed in vivo by fibrin. The fibrin compositions of the invention are compatible both in biochemical assays and cell-based assays, and thus useful for in vitro assays for screening of test agents that modulate cell activation and/or signaling pathways mediated by fibrin or associated with fibrin activity.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 22, 2019
    Assignee: THE J. DAVID GLADSTONE INSTITUTE
    Inventors: Katerina Akassoglou, Jae Kyu Ryu, Anke Meyer-Franke
  • Patent number: 10444247
    Abstract: The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNR1, P1GF2, Activin A, Ue3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 15, 2019
    Assignee: Wallac Oy
    Inventors: Pertti Hurskainen, Heikki Kouru, Mikko Sairanen, Tarja Ahola, Teemu Korpimäki
  • Patent number: 10429379
    Abstract: Disclosed herein are methods of diagnosing Rheumatoid arthritis in a subject comprising determining whether the subject is immunologically reactive with N-acetylglucosamine-6-sulfatase and/or filamin-A, wherein immunological reactivity of the subject to one or more of N-acetylglucosamine-6-sulfatase or filamin-A, as compared to an appropriate control, indicates the subject has rheumatoid arthritis. Examples of specific assays and kits for use with the methods are also disclosed.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: October 1, 2019
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Allen C. Steere, Elise E. Drouin
  • Patent number: 10416174
    Abstract: Described herein are methods and devices for diagnosing chronic fatigue syndrome using peptide arrays, and providing a prognosis to patients.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: September 17, 2019
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, WHITTEMORE PETERSON INSTITUTE
    Inventors: Stephen Albert Johnston, Phillip Stafford, Vincent Lombardi
  • Patent number: 10416173
    Abstract: The present invention relates to a method for the diagnosis of a disease or a risk for the development of a disease, in particular a disease which is mediated via the alternative pathway of the complement system. It further relates to a novel diagnostic marker and methods for identifying active agents.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: September 17, 2019
    Assignee: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Sascha Dammeier, Eloed Koertvély, Marius Ueffing
  • Patent number: 10407736
    Abstract: The disclosure provides methods for characterizing a prostate cancer sample by detecting expression of ERG, PTEN or both, changes in which relative to a normal control are shown herein to be correlated with prostate cancer capsular penetration and more aggressive forms of prostate cancer. Such methods are useful for the prognosis of prostate cancer capsular penetration and for making treatment decisions in patients with prostate cancer that has penetrated the capsule. Also provided are kits that can be used with such methods.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: September 10, 2019
    Assignees: Ventana Medical Systems, Inc., The Arizona Board of Regents on behalf of the University of Arizona
    Inventors: Gary Pestano, Ray B. Nagle, Connie Cortez, Kristie A. Vanpatten, Amit M. Algotar
  • Patent number: 10408713
    Abstract: The present invention provides a method of analyzing a sample containing an analyte to be qualitatively and/or quantitatively determined, comprising a binding step and a washing step, wherein the binding step comprises: interacting the analyte with beads having a density m1; obtaining a structure of packed beads comprising quantifiable bead complexes having a density m2; and the washing step comprises: dispersing the packed beads in a liquid medium having a density d>m2 and m1; and separating the liquid medium and the beads comprising the quantifiable bead complexes.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: September 10, 2019
    Assignee: SpinChip Diagnostics AS
    Inventors: Stig Morten Borch, Torgeir Hamsund, Jostein Geir Holtlund, Anja Gulliksen
  • Patent number: 10401368
    Abstract: Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK1 8 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unb
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: September 3, 2019
    Assignee: PDL Biopharma, Inc.
    Inventors: Jeffrey Allan Miller, Eddie Phillip Jeffries
  • Patent number: 10393747
    Abstract: This invention relates to a method for gastric cancer diagnosis through the detection of glycan changes, and to a kit for gastric cancer diagnosis. More specifically, based on the fact that in gastric cancer patient-derived haptoglobin, there are changes in N-linked glycosylation of haptoglobin, which are detected through lectin and mass spectrometery, that is, an increase in fucosylation, increases or significant changes in specific glycan structures depending on the classification of antennary structures, or a remarkable decrease in a high mannose structure of the N-glycan as compared to normal persons, N-glycan structures identified using the changes in N-linked glycosylation of haptoglobin may be usefully used as a diagnosis marker in a method for gastric cancer diagnosis using lectin or mass spectrometry, and a kit for gastric cancer diagnosis.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: August 27, 2019
    Assignee: Korea Advanced Institute of Science and Technology
    Inventors: Jung Hoe Kim, Sung Hyeon Lee, Seung Yeol Park, Jin Man Kim, Hyun Joo An, Jae-Han Kim, Myung Jin Oh
  • Patent number: 10393734
    Abstract: The present invention relates to a method for the diagnosis of a disease comprising contacting a donor tissue section with a liquid capable of extracting an antibody from said donor tissue section and contacting said liquid with an acceptor material comprising an antigen, followed by detection of a complex comprising the antibody and the antigen, and a diagnostically useful carrier comprising a donor tissue section and an acceptor material comprising an antigen.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: August 27, 2019
    Assignee: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Winfried Stoecker, Bianca Teegen, Annika Jahnke
  • Patent number: 10384174
    Abstract: The present invention relates to a particle manipulation method to disperse magnetic particles 70 in a liquid 35 filling up a tube container 10, wherein a circumferential direction moving step to move the magnetic particles 70 along the circumferential direction of the container 10 in the liquid 35 and in a radial direction moving step to move the magnetic particles 70 as crossing the radial direction of the container 10 in the liquid 35 are implemented repeatedly. Such manipulations can be achieved by combining rotation of the container and gravity force and magnetic field manipulations.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: August 20, 2019
    Assignees: SHIMADZU CORPORATION, KAZUSA DNA RESEARCH INSTITUTE
    Inventors: Jun Yanagibayashi, Tetsuo Ohashi, Osamu Ohara
  • Patent number: 10386366
    Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: August 20, 2019
    Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
    Inventors: Sharat Singh, Shui-Long Wang, Linda Ohrmund
  • Patent number: 10352920
    Abstract: Methods for monitoring and adjusting a physiological state of a subject. The methods include (1) providing a subject having one or more physiological parameters defined by one or more biometrics, (2) monitoring a selected biometric analyte associated with a selected biometric to define a state of the selected biometric, (3) based on the results of the monitoring, adjusting the state of the selected biometric by administering to the subject a supplement selected to affect the state of the selected biometric.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 16, 2019
    Assignee: i-calQ, LLC
    Inventor: Joel R. L. Ehrenkranz
  • Patent number: 10345298
    Abstract: The present invention relates to a method for diagnosing multiple sclerosis (MS) and/or clinically isolated syndrome (CIS) and/or radiologically isolated syndrome (RIS) or a predisposition for either condition in a subject, the method comprising determining the presence of an anti-KIR4.1 antibody in a sample obtained from said subject by (a) contacting said sample with a protein; and (b) detecting the formation of a protein-anti-KIR4.1 antibody complex; wherein said protein is KIR4.1, wherein glycosylation of the large extracellular domain of said KIR4.1 is as in human oligodendrocytes or glycosylation of the large extracellular domain is absent; and wherein the formation of said complex is indicative of MS, CIS, RIS or a predisposition therefore. Furthermore provided is an antibody or fragment or derivative thereof competing with the anti-KIR4.1 antibody in a sample obtained from a patient having MS.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: July 9, 2019
    Assignee: Klinikum rechts der Isar der Technischen Universität München
    Inventors: Bernhard Hemmer, Rajneesh Srivastava, Lucas Schirmer
  • Patent number: 10338083
    Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: July 2, 2019
    Assignee: NESTEC S.A.
    Inventors: Stefan Westin, Fabiyola Selvaraj, Fred Princen, Sharat Singh
  • Patent number: 10328427
    Abstract: The present invention provides an assay device for detecting an analyte in a fluid sample, comprising: a sample receiving member (1), which is fluidically connected to at least two components (2, 3) defining an assay flow path, at least one of which is a detection member (3) comprising an analyte detection zone (31); and a sample detection element (13) adapted to detect fluid at a particular point along the assay flow path. The present invention also provides the use of the assay device of the invention for indicating sample sufficiency when the assay device is exposed to a fluid sample and for indicating to a user after sampling that the device has failed due to insufficient sampling, and a method of alerting a user to the fact that a sufficient sample has been applied to an assay device of the invention.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: June 25, 2019
    Assignee: SPD SWISS PRECISION DIAGNOSTICS GMBH
    Inventors: Kieran Andrew Lehane, Steven Hart